Waters Corporation (WAT)

MILFORD, Mass., Feb. 23, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D.

Headlines: Delivers up to 2× higher sensitivity than stainless steel microflow columns, lowering detection and quantitation limits across high-throughput bioseparations, DMPK, and 'omics applications.1  Uses up to 75% less sample than 2.1 mm I.D. columns, conserving precious materials such as cell and gene therapy and personalized medicine candidates while delivering deeper insights.

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.

WAT tops Q4 estimates as revenues rise 7% Y/Y, with strong Pharma and Europe growth, and upbeat 2026 sales and earnings outlook.

Waters (WAT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Envestnet Asset Management Inc. lowered its position in Waters Corporation (NYSE: WAT) by 11.6% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 111,414 shares of the medical instruments supplier's stock after selling 14,656 shares during the quarter. Envestnet Asset

BDX completes its Biosciences & Diagnostic spin-off and Waters merger, securing $4B in proceeds as it pivots to a pure-play MedTech focus.

Revenue Growth: 7% reported growth and 6% constant currency growth for Q4 2025.Adjusted EPS: Increased by low double digits to $4.53 for Q4 2025.GAAP EPS: $3.7

The Dow tapped a new record higher while other major indexes rose, thanks to a bounce back in tech and software stocks

Waters Corporation (WAT) Q4 2025 Earnings Call Transcript

Waters (WAT) came out with quarterly earnings of $4.53 per share, beating the Zacks Consensus Estimate of $4.5 per share. This compares to earnings of $4.1 per share a year ago.

FRANKLIN LAKES, N.J., Feb. 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) today announced the successful completion of the previously announced spin-off of BD's Biosciences & Diagnostic Solutions business and the combination of the business with Waters Corporation (NYSE: WAT).

Announces appointment of Claire M. Fraser, Ph.D.

Stock News Japan rally on election landslide: Japanese stocks hit record highs after Prime Minister Sanae Takaichi's coalition secured a two-thirds lower-house

Highlights Fourth Quarter 2025 Sales of $932 million landed at the high-end of reported sales growth guidance range; grew 7% as reported and 6% in constant currency Growth led by high single-digit constant currency growth in Pharma and Industrial end-markets, with broad-based growth across all regions Chemistry grew 12% in constant currency as new bioseparations products continued to experience significant customer demand Instruments grew 3% in constant currency, with high single-digit LC-MS growth partially offset by TA and transition to subscription model for Empower GAAP EPS of $3.77; non-GAAP EPS of $4.53 grew double digits Full-Year 2025 Sales of $3,165 million grew 7% as reported and 7% in constant currency Instruments grew 5% in constant currency, led by strong LC-MS growth Recurring Revenue grew 8% in constant currency, led by 12% Chemistry growth GAAP EPS of $10.76; non-GAAP EPS of $13.13 grew double digits MILFORD, Mass., Feb. 9, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT), today announced its financial results for the fourth quarter and full year 2025.

Waters (WAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.